Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder
0.350 Biomarker disease BEFREE Further studies in independent and larger cohorts are warranted to confirm the involvement of IGFBP2 in BD. 28090803 2018
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder
0.350 Biomarker disease BEFREE The most common adverse event was skin rash: 22.0% for BP-I, 16.7% for BP-II, and 12.1% for BP-NOS. 28360522 2017
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder
0.350 AlteredExpression disease BEFREE Decreased expression of insulin-like growth factor binding protein 2 in the prefrontal cortex of subjects with bipolar disorder and its regulation by lithium treatment. 17395163 2007
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder
0.350 Biomarker disease PSYGENET We found decreased IGFBP-2 expression in bipolar disorder patients compared with controls; this was especially pronounced in subjects not treated with lithium. 17395163 2007
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder
0.350 Biomarker disease PSYGENET The continuity/spectrum between BP (mainly BP-II) and MDD was supported by the following findings:(1) high frequency of mixed states (mixed mania, mixed hypomania, mixed depression, i.e. co-occurring depression and noneuphoric manic/hypomanic symptoms) because opposite polarity symptoms in the same episode do not support a hypomania/mania-depression splitting; (2) MDD was the most common mood disorder in BP probands' relatives; (3) no bimodal distribution of distinguishing symptoms between BP and MDD; (4) bipolar signs not uncommon in MDD; (5) many MDD shifting to BP; (6) many lifetime manic/hypomanic symptoms in MDD; (7) correlation between lifetime manic/hypomanic symptoms and MDD symptoms; (8) hypomania factors in MDD; (9) MDD often recurrent; (10) similar cognitive style. 17230047 2007
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder
0.350 AlteredExpression disease LHGDN We found decreased IGFBP-2 expression in bipolar disorder patients compared with controls; this was especially pronounced in subjects not treated with lithium. 17395163 2007
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder
0.350 Biomarker disease BEFREE The continuity/spectrum between BP (mainly BP-II) and MDD was supported by the following findings:(1) high frequency of mixed states (mixed mania, mixed hypomania, mixed depression, i.e. co-occurring depression and noneuphoric manic/hypomanic symptoms) because opposite polarity symptoms in the same episode do not support a hypomania/mania-depression splitting; (2) MDD was the most common mood disorder in BP probands' relatives; (3) no bimodal distribution of distinguishing symptoms between BP and MDD; (4) bipolar signs not uncommon in MDD; (5) many MDD shifting to BP; (6) many lifetime manic/hypomanic symptoms in MDD; (7) correlation between lifetime manic/hypomanic symptoms and MDD symptoms; (8) hypomania factors in MDD; (9) MDD often recurrent; (10) similar cognitive style. 17230047 2007
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder
0.350 Biomarker disease PSYGENET Efforts to dissect BPAD have been based on the course of the disorders (BP I versus BP II or rapid cycling), comorbidity pattern (panic attacks, suicide attempts, addiction or hyperactivity), differences between the sexes, and clinical pattern (cycloid and puerperal psychosis). 15762851 2005
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder
0.350 Biomarker disease BEFREE Efforts to dissect BPAD have been based on the course of the disorders (BP I versus BP II or rapid cycling), comorbidity pattern (panic attacks, suicide attempts, addiction or hyperactivity), differences between the sexes, and clinical pattern (cycloid and puerperal psychosis). 15762851 2005